Highlights from IMS 20th meeting 2023



30-31 gennaio 2024 BOLOGNA, Royal Hotel Carlton

Disclosures

	Speaking fees	Advisory boards	Research support
Amgen	x	x	
BMS/Celgene	х	x	X
GSK		x	
Karyopharm		x	
Janssen	X	x	X
Sanofi	х	x	Х
Takeda	X	X	

Highlights from IMS 20th meeting 2023

DEFINITIONS

Plasmocytoma


Monoclonal proliferation of plasma cells forming a tumor mass

Extramedullary Plasmocytoma

Plasma cell tumor of soft tissue

Paraosseous Plasmocytoma

Plasmocytoma that arises from skeletal focal lesions, disrupts the cortical bone and grows as extrabone masses



Extramedullary disease is characterised by:

- High incidence of high risk FISH, in particular: del(17p), amp(1q) and t(4;14)

- High ki67

- Abnormal expression of **adhesion proteins**

In particular:

- del (17p) \rightarrow 34% in EMD vs 11% in MM

- **Ki-67** \rightarrow 67% (range, 30–90%)


- CD56 \rightarrow lower expression in EMD respect to MM (15% vs 80%)

Deng S et al. Clin Lymphoma Myeloma Leuk, 2015 Rasche L et al. Ann Hematol, 2012 Katodritou E. Leukemia Res, 2009

Reduced expression of therapeutic targets




3 at diagnosis




Highlights from IMS 20th meeting 2023

BIOLOGICAL FEATURES OF EXTRAMEDULLARY PLASMOCYTOMAS

Plasma cell trafficking



Immunoediting of the tumor microenvironment



IMiDs-treated relapsed MM with EMD

Thalidomide \rightarrow IneffectiveLenalidomide \rightarrow IneffectivePomalidomide \rightarrow Not very effective

CELLMoDs \rightarrow No data


Isatuximab-treated relapsed MM with EMD (IsaPd vs Pd – Ikaria study)


154 pts in Isa-Pd \rightarrow 24 pts with EMD 153 pts in Pd \rightarrow 24 pts with EMD



Median 4.6 months Median 1.6 months

Isatuximab-treated relapsed MM with EMD (IsaKd vs Kd – Ikema study)





HR 0.2

Daratumumab-treated relapsed MM with EMD (retrospective monocentric experience)


13 pts with relapsed MM and EMD Median PFS 6,5 months

Daratumumab-treated relapsed MM with EMD (Sirius subgroup analysis)

14 pts with relapsed MM and EMD **ORR 3 (21%) pts**

Jullien M et al. Annals of Hematol 2019 Lonial S et al. Lancet 2016

Carfilzomib-treated relapsed MM with plasmocytomas



Selinexor-treated relapsed MM with EMD (SelDex – STORM study)

122 penta-refractory patients enrolled in the study.


27 patients with plasmocytoma: 22 EMD + 5 paraosseous disease

16 evaluable patients: 4 PR + 1 VGPR

Melflufen-treated relapsed MM with EMD (MelflufenDex – Horizon study)

121 triple refractory patients enrolled in the study.

44 patients with plasmocytoma: 26 EMD + 18 paraosseous disease



Richardson P et al. Clin Lymph Myeloma Leuk 2019

Bispecific-treated relapsed MM with EMD (Teclistamab – Majestec study)

165 pts dosed with teclistamab

28 pts (17%) had EMD

 ORR
 69% no-EMD

 36% EMD

Moreau P et al. NEJM 2022

Bispecific-treated relapsed MM with EMD (Real world evidence)

106 pts treated with **teclistamab** in the real world setting

100% <u>triple-class exposed</u>64% were <u>penta-class refractory</u>53% previously treated with an <u>BCMA-directed therapy</u>




In multivariate analysis EMD was a strong predictor of lower PFS

Talquetamab-treated relapsed MM with EMD (MonumenTAL1 study)

143 pts treated with talquetamab at full dose

100% <u>triple-class exposed</u> 98% were <u>penta-class exposed</u> 24% had EMD

Responses: ORR



CiltaCel-treated relapsed MM with EMD (Cartitude 1 study)

113 pts (97 infused) treated with CiltaCell**19 pts** with plasmocytoma (EMD + PO)



*Median follow-up 22 months


Jakubowiak A et al. ASH 2021

OS

Humanized anti-BCMA CAR-T

Small experience in 20 heavily-treated MM pts

PFS



Deng H et al. Frontiers Immunol. 2021

Mayo Clinic Real world experience

20 pts with secondary EMD treated with CAR-T.



12 pts with secondary EMD treated with **Bispecific antibodies**.



Zanwar S et al. Am J Hematology 2023

CONCLUSIONS

EMD represents the worst challenge in MM patients.

EMD recapitulates the worst adverse biological factors (FISH, high prolifertive rate....

EMD is well equipped to withstand immunotherapy.

EMD is uncommon, and this impairs the clinical research.